This is a working overview of Research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-28. Anything still debated is marked as such rather than presented as settled.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
| Property | Value | Notes |
|---|---|---|
| Common route | Intranasal | Also injected in some animal work |
| Solubility class | Freely soluble in water | Solid form is hygroscopic |
| Typical storage | About -20 degrees Celsius | Keep desiccated and dark |
| Purity method | Reverse-phase HPLC | Reported as area percent |
| Confirmatory method | Mass spectrometry | Verifies expected molecular mass |
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Deep, superficial, and perforator veins The three main compartments of the venous system are the deep veins, the superficial veins, and the perforator veins. Superficial veins are those closer to the surface of the body, and have no corresponding arteries. Deep veins are deeper in the body and have corresponding arteries. Perforator veins drain from the superficial to the deep veins. These are usually referred to in the lower limbs and feet. Superficial veins include the very small spider veins of between 0.5 and 1 mm diameter, and reticular or feeder veins.
Creatine kinase S-type, mitochondrial is an enzyme that in humans is encoded by the CKMT2 gene. Mitochondrial creatine kinase (MtCK) is responsible for the transfer of high energy phosphate from mitochondria to the cytosolic carrier, creatine. The "energy-rich" gamma-phosphate group of ATP that is generated by oxidative phosphorylation inside mitochondria is trans-phosphorylated to creatine (Cr) to give phospho-creatine (PCr), which then is exported from the mitochondria into the cytosol, where it is made available to cytosolic creatine kinases (CK) for in situ regeneration of the ATP that has been used for cellular work. Cr then is returning to the mitochondria where it stimulates mitochondrial respiration and again is charged-up by mitochondrial ATP via MtCK. This process is termed the PCr/Cr-shuttle or circuit. MtCK belongs to the creatine kinase (CK) isoenzyme family. It exists as two isoenzymes, sarcomeric MtCK and ubiquitous MtCK, encoded by separate genes. Mitochondrial creatine kinase occurs in two different oligomeric forms: dimers and octamers, in contrast to the exclusively dimeric cytosolic creatine kinase isoenzymes. Sarcomeric mitochondrial creatine kinase has 80% homology with the coding exons of ubiquitous mitochondrial creatine kinase. This gene contains sequences homologous to several motifs that are shared among some nuclear genes encoding mitochondrial proteins and thus may be essential for the coordinated activation of these genes during mitochondrial biogenesis.
==== Eukaryotic algae ==== In nearly all species of eukaryotic algae (Chloromonas being one notable exception), upon induction of the CCM, ~95% of RuBisCO is densely packed into a single subcellular compartment: the pyrenoid. Carbon dioxide is concentrated in this compartment using a combination of CO2 pumps, bicarbonate pumps, and carbonic anhydrases. The pyrenoid is not a membrane-bound compartment but is found within the chloroplast, often surrounded by a starch sheath (which is not thought to serve a function in the CCM).
Sources: en.wikipedia.org
Sinfield, who now favoured a softer approach, took lyrical inspiration from Homer's Odyssey, musical inspiration from jazz players like Miles Davis and Ahmad Jamal, and a trip to the Balearic Islands. Islands featured the instrumental "Sailor's Tale", with a droning Mellotron and Fripp's banjo-inspired guitar solo; the raunchy blues-rocker "Ladies of the Road", a tribute to groupies that featured Wallace and Collins singing Beatlesque backing vocals; and "Song of the Gulls", which was developed from the instrumental "Suite No. 1" from Giles, Giles & Fripp's 1968 album and would be the only time the band would utilize an orchestra. Burrell disliked Sinfield's lyrics, and one of the band members allegedly called Islands "an airy-fairy piece of shit". Released in December 1971, Islands charted at No. 30 in the UK and No. 76 in the US. That same month, the band undertook a short tour of the United States, after which Fripp informed Sinfield that he could no longer work with him and asked him to leave King Crimson. In January 1972, the remaining four members broke up acrimoniously in rehearsals, owing partially to Fripp's refusal to play a composition by Collins. He later cited this as "quality control", with the idea that King Crimson would perform the "right" kind of music. In order to fulfill touring contracts in the United States in 1972, Fripp, Collins, Burrell, and Wallace reformed with the intention of disbanding immediately after the tour. Recordings from various North American dates during January and February 1972 were released as Earthbound in June of that year.
The CAP has three main parts. First, the European Agricultural Guarantee Fund distributes 'direct payments', which are 70.9% of the CAP budget. The Direct Payments Regulation 2013 gives payments to an 'active farmer' that carries out agricultural activity, grazing or cultivation, does not operate airports, rail, waterworks, real estate, sport or recreation grounds, and has the land at their disposal. The farm must have at least 1 hectare and receive €100 for each, though member states can set higher thresholds (e.g. 5 hectares and €200). If payments reach over €150,000 there is a 5% reduction per hectare for each hectare. This favours large farm corporations, and the largest 1% typically receive around 10 to 15% of all subsidies in member states. As conditions of receiving subsidies, farms can be required to keep land in good condition, for public, animal, and plant health, and maintain environment standards. For minimal biodiversity, farmers must have over two crops if they have 10 hectares, not farm at least 5% of lintensively (an 'ecological focus area' over 15 hectares, and have three crops over 30 hectares. Environmentally sensitive grasslands, as designated by the Habitats Directive 1992 and the Wild Birds Directive 2009, should not be more turned into more than 5% agricultural area. The second main part, also carried out by the EAGF, is 'market measures'. Under the Agricultural Products Regulation 2013 certain crops and meat are eligible for purchase by member state authorities, to be 'stored by them until disposed of', with extra aid for storage.
=== Muscles === People with DM experience progressively worsening muscle weakness in the proximal muscles (for example, the shoulders and thighs). Tasks that use these muscles: standing from sitting, lifting, and climbing stairs, can become increasingly difficult for people with dermatomyositis.
Sources: en.wikipedia.org
== Further reading == Chesnut, D. B.; Savin, A. (1999). "The Electron Localization Function (ELF) Description of the PO Bond in Phosphine Oxide". Journal of the American Chemical Society. 121 (10): 2335–2336. Bibcode:1999JAChS.121.2335C. doi:10.1021/ja984314m. Alkorta, Ibon; Sánchez-Sanz, Goar; Elguero, José; Del Bene, Janet E. (2014). "Pnicogen Bonds between X═PH3 (X = O, S, NH, CH2) and Phosphorus and Nitrogen Bases". The Journal of Physical Chemistry A. 118 (8): 1527–1537. Bibcode:2014JPCA..118.1527A. doi:10.1021/jp411623h. PMID 24547683.
Inputs: elements needed for production; seeds, fertilizers, agrochemicals, farm equipment, irrigation equipment, GMO technology Production for export: includes fruit and vegetables production and all processes related to growth and harvesting; planting, weeding, spraying, picking Packing and cold storage: grading, washing, trimming, chopping, mixing, packing, labeling, blast chilling Processed fruit and vegetables: dried, frozen, preserved, juices, pulps; mostly for increasing shelf life Distribution and marketing: supermarkets, small scale retailers, wholesalers, food service
Microbubbles are bubbles smaller than one hundredth of a millimetre in diameter, but larger than one micrometre. They have widespread application in industry, medicine, life science, and food technology. The composition of the bubble shell and filling material determine important design features such as buoyancy, crush strength, thermal conductivity, and acoustic properties. They are used in medical diagnostics as a contrast agent for ultrasound imaging. The gas-filled microbubbles, typically air or perfluorocarbon, oscillate, and vibrate if a sonic energy field is applied and may reflect ultrasound waves. This distinguishes the microbubbles from surrounding tissues. Because gas bubbles in liquid lack stability and would therefore quickly dissolve, microbubbles are typically encapsulated by shells. The shell is made from elastic, viscoelastic, or viscous material. Common shell materials are lipid, albumin, and protein. Materials having a hydrophilic outer layer to interact with the bloodstream and a hydrophobic inner layer to house the gas molecules are thermodynamically stable. Air, sulfur hexafluoride, and perfluorocarbon gases all can serve as the composition of the microbubble interior. Microbubbles with one or more incompressible liquid or solid cores surrounded by gas are referred to as microscopic or endoskeletal antibubbles. For increased stability and persistence in the bloodstream, gases with high molecular weight as well as low solubility in the blood are attractive candidates for microbubble gas cores.
Sources: en.wikipedia.org
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.
Reported human trials are few, brief and originate mainly from one country. They describe effects on anxiety-related measures, but sample sizes are small and reporting is limited. The results are widely regarded as preliminary rather than confirmed.
Reverse-phase liquid chromatography is used to assess purity and separation of related impurities. Mass spectrometry confirms that the observed molecular mass matches the expected peptide. A certificate of analysis from the supplier is the usual document of record.
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.